Product Information

• Package Insert - Gamunex-C (PDF - 2.7MB)

Supporting Information

• October 13, 2010 Approval Letter - Gamunex-C
  New route of administration, subcutaneous administration, for the treatment of Primary Humoral Immunodeficiency.
• September 12, 2008 Approval Letter - Gamunex-C
  Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.
• August 27, 2003 Approval Letter
  Indication: Primary humoral immunodeficiency and idiopathic thrombocytopenic purpura.
• FDA Approves Treatment for Rare Neurologic Disease
  Press Release: September 12, 2008

Contact FDA